Business Context and Reporting Period
This Form 6-K filing by Icecure Medical Ltd. covers the month of October 2023, specifically dated October 5, 2023. The report serves to disseminate a press release regarding clinical study results for the Company's ProSense technology.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical developments rather than financial performance.
Material Changes
The primary material change reported is the publication of results from an independent study performed in Italy. The study demonstrated that women deemed inoperable for breast cancer benefited from Icecure Medical's ProSense, showing a tumor reduction rate ranging from 93.43% to 96.81%.
Guidance, Outlook, and Risks
The press release incorporates a section titled "Forward Looking Statements" into the Company's Registration Statements on Form F-3 and Form S-8. The filing does not provide specific numerical guidance or detailed risk factors beyond the standard incorporation of forward-looking language.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed methodology of the Italian study.
- Review the incorporated "Forward Looking Statements" in the referenced Form F-3 and Form S-8 registration statements for specific risk disclosures.
- Confirm the regulatory status of ProSense in Italy and other jurisdictions following these results.
- Check subsequent filings for any financial impact or commercialization plans resulting from this study.